Digital Asset DirectUnicycive Therapeautics, Inc.
Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/
November 08, 2022 09:00 AM Eastern Standard Time
Video
News ReleaseElsevier
New ‘Confidence in research: researchers in the spotlight’ report by Economist Impact, supported by Elsevier, reveals researchers’ outlook on global research landscape and concerns around misinformation, online abuse and widening of inequalities. Researchers are concerned about the challenges of greater public interest in scientific research, but the majority believe it has never been more important for them to engage in debate and help counter false information. The landmark ‘Confidence in research: researchers in the spotlight’ report published today finds that nearly two thirds of scientific researchers surveyed (63%) feel the pandemic has increased public attention on research. But only 38% think that better public understanding of research will be a legacy of the pandemic. (i) Conducted by Economist Impact and supported by Elsevier, a global leader in scientific publishing and information analytics, the report combines the findings from a global survey of over 3,000 scientists, scholars and researchers on how the pandemic has affected the practice of undertaking and communicating research in the face of increased public scrutiny. The full report includes recommendations for potential solutions from a Global Expert Panel of researchers, academic leaders, science organisations and policy makers. Being published in a peer-reviewed journal is the most important marker of reliability according to 74% of researchers surveyed. The study also reveals that more than half of researchers (52%) feel the pandemic increased the importance of publishing research early, prior to peer review, and many – particularly women, early career researchers and those in Global South countries – feel the pandemic has widened inequalities in, and access to, funding in their fields. More than half of respondents expressed concern about the challenges of over-simplification(52%) and the politicisation of research (56%) because of increased public attention and social media focus on research and the research process. As a result, many say they now lack confidence in their ability to communicate their findings to the public in this new environment. Fewer than one in five researchers (18%) participating in the study feel highly confident in communicating their findings on social media. This is against a background of nearly a third (32%) of respondents having experienced, or knowing a close colleague who has experienced abuse after posting research online. Half of all researchers surveyed (51%) say they feel a responsibility to engage in debate online and over two thirds (69%) believe the pandemic has increased the importance of separating quality research from misinformation. In fact, misinformation has become such a concern globally in recent years that nearly a quarter of academics (23%) now see publicly countering it as one of their primary roles in society, compared to just 16% who said this was the case before the pandemic. Alongside supporting the landmark survey by Economist Impact, Elsevier partnered with leading science and research organisations (ii) to bring together world-renowned experts, academic leaders and early career researchers to explore the impact of the pandemic on researchers and to identify potential areas of action to help the research community and enhance confidence in research. Economist Impact has combined the findings from the global survey with the insights from the extensive stakeholder dialogue to develop recommendations, which are set out in the ‘Confidence in research: researchers in the spotlight’ report published today. These include: Providing formal communications training to give researchers the tools and guidance to communicate ethically, effectively and with confidence, and incentivising strong communication skills as part of career development; Providing support for researchers in the face of online abuse by drafting clear codes of conduct and guidance on how to manage online interaction; Embedding the right incentive and reward structures to ensure that researchers’ contribution to furthering confidence in science receives appropriate recognition, in particular their role in teaching, public engagement and participation in the peer review process; Promoting collaboration and impact by providing financial incentives for researchers to collaborate in larger teams and facilitate quality trials and studies over quantity; Prioritising equity and diversity by directing research funding to countries and research communities that need it most; Adopting more digestible summaries and user-friendly formats to make it easier for policymakers, journalists or the general public to better understand and identify quality research; Prioritising consistency in R&D spending to ensure that researchers can properly plan their research, staffing and infrastructure needs. Laura Hassink, Managing Director of Scientific, Technical and Medical Journals at Elsevier, said: “The pandemic showed just how important quality research is for addressing global challenges and accelerating progress for society. Science is advancing at an extraordinary pace but that has brought new pressures on researchers such as tackling damaging misinformation, handling public scrutiny, and communicating their work with confidence. The Economist Impact report can be a helpful stimulus as all stakeholders in research come together to turn recommendations into action. At Elsevier, we are committed to supporting the research community to tackle these challenges and thank our expert partners and the thousands of academic leaders, scientists and researchers who lent their invaluable perspectives to this important collaboration.” Tracey Brown, Director, Sense about Science, and chair of a Global Expert Panel that discussed the findings said: “People who use research evidence need to know what weight they can put on it, and the pandemic exploded the numbers of people who use research evidence by millions. Researchers had to bring decision makers, the public and reporters in on all those questions about how reliable a study is, and how convincing its findings are. And they did this – they did it incredibly well the world over, with innovation and determination, but at some price. This research is a step to figuring out how to take the benefits forward, and address the challenges that make it unnecessarily difficult to talk about what we know and how.” Jonathan Birdwell, Regional Head of Policy Research & Insights for EMEA, Economist Impact said: “The pandemic demonstrated the research community’s ability to come together and solve global problems. It increased public attention on that community like never before, presenting opportunities for open science and policy influence, but also challenges around higher volume, speed and demand for simple stories. But do researchers have confidence to embrace a more public-facing role? And are their support structures and incentives fit-for-purpose amidst this new landscape? Our research finds that many researchers want to solve societal problems, influence policy and boost public understanding of research. But to do so confidently, they need more time to devote to communication, support in the face of online abuse and recognition of their public-facing contributions.” Notes to editors Statistical references / methodology (i) Economist Impact’s research was conducted with 3,144 active researchers globally between May and August 2022, spanning 100 countries and dozens of fields of expertise. (N.B. active is defined as having published an article within the last three years). This quantitative research was informed by a literature review and supplemented with qualitative in-depth interviews with a range of independent research experts, plus a Global Advisory Board. (ii) In addition to the quantitative survey and expert interviews, insights were also gathered from six regional roundtables led by Elsevier’s regional convening partners: Chinese Association for Science of Science and Science & Technology Policy (China) Japanese Association for the of Advancement Science (Japan) Koninklijke Hollandsche Maatschappij der Wetenschappen, (Netherlands) Körber Stiftung (Germany) Research!America (United States) Sense about Science (UK) Combined, these roundtables featured the perspectives of around 200 researchers covering approximately 14 countries. (iii) The survey findings, insights from the qualitative in-depth interviews and the regional roundtables were discussed by a Global Expert Panel, convened by Elsevier, which contributed recommendations for action and further exploration. These were collated by the Economist Impact and set out in the full report. More information on the methodology of the study and a full list of the experts consulted can be viewed via the report. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,700+ journals, including The Lancet and Cell; our 43,000+ eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com About Economist Impact Economist Impact combines the rigour of a think-tank with the creativity of a media brand to engage a globally influential audience. We believe that evidence-based insights can open debate, broaden perspectives and catalyse progress across three core areas of expertise and leadership including sustainability, new globalisation and health. The services offered by Economist Impact previously existed within The Economist Group as separate entities, including EIU Thought Leadership, EIU Public Policy, Economist Events and SignalNoise. Our track record spans 75 years across 205 countries. Along with creative storytelling, events expertise, design-thinking solutions and market-leading media products, we produce framework design, benchmarking, economic and social impact analysis, forecasting and scenario modelling, making Economist Impact's offering unique in the marketplace. Visit www.economistimpact.com for more information. About Sense about Science Sense about Science is an independent non-profit that promotes the public interest in sound science and evidence. It produced the first public guide to peer review, ‘I Don’t Know What to Believe’ over a decade ago, and has since produced the first international guide to data science, co-created with user groups around the world. With its AllTrials campaign, with patients, doctors and researchers, it has achieved major changes in international regulation and compliance on the publication of clinical trial results. Sense about Science chaired the Global Expert Panel, to develop plans for improving scientific practices and helping researchers and the public to navigate research outputs. It represents UK-based stakeholders as the local Regional Convening Partner, to draw people into a discussion of what actions and interventions researchers, scholarly publishers, universities, funders and others can make to improve confidence in research in the UK. Media contacts Andrea White Elsevier Global Communications +44 7876 397206 a.white@elsevier.com Dan DiPietro-James Global Media Relations Director +1 773-251-8744 dan.james@elsevier.com Esra Erkal EVP Global Communications +44 7500 992819 e.erkal@elsevier.com Claudine Cornelis Economist Impact claudinecornelis@economist.com Harry Saunders Teneo +44 7901 313198 Harry.Saunders@teneo.com Contact Details Dan DiPietro-James dan.james@elsevier.com Company Website https://www.elsevier.com/
November 07, 2022 07:01 PM Eastern Standard Time
News ReleaseSunshine Biopharma Inc.
The generic drug market has been growing since 1984 when the Hatch-Waxman Act encouraged manufacturing generics and developed a framework to regulate them. Apart from name difference, generic drugs work the same as an already marketed brand-name drug in dosage form, safety, strength, administration, quality, performance characteristics and intended use. Generic drug manufacturers can apply to the U.S. Food and Drug Administration (FDA) for permission to produce drugs when a patent expires. Generic drugs typically cost 80% to 85% less than branded drugs. If you look at your medications, chances are you will find one or more generic drugs such as ibuprofen, famotidine, metformin, metoprolol and amphetamine salt combo. Growing Global Generic Drugs Market The popularity, need for and use of these drugs are fueling the growth of the global generic drug market, which is expected to grow at a compound annual growth rate (CAGR) of 7.24% from 2022 to 2027. The market is expected to be worth $311.8 billion this year and $442.3 billion by 2027. Companies like Sol-Gel Technologies Ltd. (NASDAQ: SLGL), Viatris Inc. (NASDAQ: VTRS) and Sunshine Biopharma Inc. (NASDAQ: SBFM) are researching, running trials and releasing products to meet demand. Strategic Acquisition By Sunshine Biopharma As the market continues to grow, strategic acquisitions like Sunshine Biopharma ’s recent purchase of Nora Pharma Inc. could help shape the future of the generic drugs market. Nora Pharma is now a wholly owned subsidiary of Sunshine after the acquisition of its outstanding shares. The purchase price of approximately $21.9 million was paid by cash, Sunshine Biopharma common stock, and an earn-out amount. Nora Pharma is one of North America’s fastest-growing generic pharmaceutical companies, according to the news release issued Oct. 20. This acquisition allows Sunshine Biopharma to expand its operations into generic prescription drugs and biosimilars. “The strategic acquisition of Nora Pharma significantly expands our revenue stream and is expected to generate multiyear top-line and bottom-line growth going forward,” Sunshine Biopharma CEO Steve Slilaty said. “This acquisition gives Sunshine a solid position in the generic prescription drugs industry and brings us closer to our objective of becoming a fully integrated pharma company.” Nora Pharma Founder and President said Sunshine will provide additional expertise that will help Nora with its accelerated growth plan to provide high-quality, affordable medicines to the Canadian market. Nora Pharma has 36 employees working at its 15,000-square-foot Health Canada-certified facility and offers over 50 pharmaceutical products, including generic prescription drugs, over-the-counter products and biosimilars. Nora Pharma and its service arm, which commercializes under the name Lea Solutions, will continue to operate without changes. “Nora Pharma will operate as a subsidiary of Sunshine Biopharma, with Mr. Chamoun as president,” Slilaty said. “We are happy to have the Nora employees join the Sunshine Biopharma family.” About Sunshine Biopharma Sunshine Biopharma (NASDAQ: SBFM) is a fully integrated pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. In addition to working with the University of Arizona to develop a treatment for COVID-19, the company also develops Adva-27a, a unique anti-cancer compound. Sunshine Biopharma reports that tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying multidrug-resistant cancer cells, including pancreatic, small-cell lung, breast and uterine sarcoma cancer cells. Clinical trials for pancreatic cancer indication will be conducted at McGill University’s Jewish General Hospital in Montreal, Canada, the company said. Sunshine Biopharma is also engaged in developing a novel anti-cancer mRNA called K1.1. The company says the data collected to date has shown that K1.1 mRNA is capable of destroying cancer cells in vitro, including multidrug-resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3) and pancreatic cancer cells (SUIT-2). Studies using nontransformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects. K1.1 mRNA is readily adaptable for delivery to patients using the proven mRNA vaccine technology. Learn more about the company here. In addition to working with the University of Arizona on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is also engaged in the development of a novel anticancer mRNA called K1.1. The data collected to date have shown that K1.1 mRNA is capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Studies using non-transformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects. K1.1 mRNA is readily adaptable for delivery into patients using the proven mRNA vaccine technology. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR +1 917-633-8980 investors@sunshinebiopharma.com Company Website https://sunshinebiopharma.com/
November 07, 2022 09:28 AM Eastern Standard Time
Video
News ReleaseYourUpdateTV
Flu season has almost always been a predictable part of every winter, but the COVID-19 pandemic threw things out of whack. The 2020-2021 flu season was practically non-existent due to COVID-19 precautions and lockdowns, and last year’s flu season was definitely mild compared to pre-pandemic years. Recently, Best-Selling Author and Medical Contributor Dr. Ian Smith teamed up with Mucinex on a nationwide satellite media tour to discuss the upcoming cold and flu season and some resources that can help. A video accompanying this announcement is available at: https://youtu.be/c4AY6pLO1kU Many health experts are predicting the 2022-2023 flu season will be a severe one, due to several factors. The main reason the flu basically disappeared the last two years was the behavior changes people made to avoid COVID – staying home, avoiding public gatherings, wearing masks, and not traveling. That also prevented the flu virus from spreading like usual. Those measures have been mostly abandoned – in addition, without the last two ‘flu seasons’ many individuals’ immunity to seasonal flu will be decreased. It is possible that we could see a higher rate of severe illness due to the flu this year. Many experts have looked to Australia, where flu season runs from April to September. They are just coming out their most devastating flu season in five years, which could be a precursor as to what we can expect to see in the U.S. The best way to prevent and limit the effects if you do contact the flu is to get vaccinated. It can take up to two weeks for the vaccine to be most effective after administration, and since the influenza virus is already circulating, it is best to do this as soon as possible. Key preventative measures like washing your hands often and covering your nose and mouth with a tissue when you cough or sneeze and sneezing into your elbow if you don’t have a tissue can be extremely effective in preventing the spread of germs. If you do find yourself with flu-like symptoms, such as cough and congestion, there are options available to help you feel better and over-the-counter remedies are the first stop. While over-the-counter remedies don’t cure the flu virus, they can go a long way towards helping treat the symptoms. Dr. Ian’s go-to is Mucinex Extended-Release Tablets, because they are clinically proven to last up to 12 hours. As the #1 pharmacist recommended expectorant, Mucinex Extended-Release Tablets relieve chest congestion and thin and loosen mucus, which can provide relief for your chest congestion, making your cough more productive. People must use over-the-counter products as directed. If symptoms persist, you should contact your healthcare professional and get checked out if deemed necessary. You can find Mucinex online at Mucinex.com or stop by Walmart or your local pharmacy retailer. About Dr Ian Smith Dr. Ian Smith is the author of the #1 New York Times bestselling books, SHRED: THE REVOLUTIONARY DIET, and SUPER SHRED: The Big Results Diet, and BLAST THE SUGAR OUT. Dr. Smith’s highly anticipated newest book, The Clean 20, became an instant New York Times best seller, helping hundreds of thousands of people reduce bad sugars from their diet, lose weight, lower blood sugar levels, and cut the cravings. Dr. Smith was appointed by President Obama to a second term on the prestigious President’s Council on Fitness, Sports, and Nutrition. He is currently the medical contributor and co-host of the nationally syndicated television show The Rachael Ray Show. He is a former co-host of the Emmy award winning syndicated daytime talk show, The Doctors. He also served as the medical/diet expert for six seasons on VH1’s highly-rated Celebrity Fit Club, and is the creator and founder of the national health initiatives The 50 Million Pound Challenge and The Makeover Mile. Dr. Smith is the former medical correspondent for NBC News network and for NewsChannel 4 in New York, where he filed reports for NBC Nightly News and The Today Show as well as WNBC’s various news broadcasts. He has appeared extensively on various broadcasts including The Oprah Winfrey Show, The View, Dr. Oz, Steve Harvey Show, The Talk, Larry King Live, Anderson Cooper 360, CNN, MSNBC and many more. He has written for various publications including Time, Newsweek, Men’s Fitness, and the New York Daily News, and has been featured in several other publications including, People, Redbook, Details Magazine, Essence, Ebony, University of Chicago Medicine on the Midway, Cosmopolitan, and Black Enterprise. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
November 04, 2022 10:05 AM Eastern Daylight Time
Video
News ReleaseAmeriLife
AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions, announced today that it has partnered with Willamette Valley Benefits. Under the leadership of longtime industry veteran and CEO Elma Friend, Willamette Valley Benefits specializes in the marketing and distribution of Medicare Advantage, Medicare Supplement, and ancillary health solutions to clients throughout the Pacific Northwest and Mountain West. Per the agreement, terms of the deal were not disclosed. "This is an exciting time for women in this industry,” said Friend. “We are a women-owned and operated business and have continued to see growth. I believe in the nurturing, compassionate side of what we do and taking care of people is our priority. As a female-driven operation, we continue to see more women entering this field and it’s a great fit because AmeriLife understands that diverse, empowered and client-first agents are key to delivering the right solutions and service.” Headquartered in Portland, OR., Willamette Valley Benefits has, for more than 16 years, helped clients navigate the complexities of healthcare via a dedicated staff of Medicare and health insurance professionals. Friend, also its founder, started with HealthNet and in launching Willamette Valley Benefits, committed herself and her firm to being a service-oriented business. Today, Willamette Valley Benefits takes a supportive approach when it comes to bringing in new agents. They collaborate with them consistently on education, service, compliance and support, ensuring that each agent has what they need to build their book of business and have a better work-life balance. Willamette Valley Benefits’ growing team currently serves communities in Oregon, Washington, Arizona and Idaho, and has recently branched into Texas. Already deeply familiar with AmeriLife through its longstanding relationship with Jack Schroeder and Associates, Willamette Valley Benefits will now have full access to AmeriLife’s best-in-class technology and resources and leading distribution platform, positioning the firm for significant growth. “Willamette Valley Benefits is, without a doubt, representative of the new face of our industry,” said Mike Vietri, AmeriLife’s Chief Distribution Officer. “AmeriLife is excited to add such a diverse and performative agency to its portfolio of companies. We look forward to working with Elma and her team to grow their operations and empower more of their agents to help people live longer, healthier lives.” ### About Willamette Valley Benefits Willamette Valley Benefits, Inc. is a local independent Medicare and health insurance agency based in Milwaukie, OR. With a passion for helping clients navigate their insurance needs, they are committed to making sure the information clients receive is clear and understandable. The team collaborates directly with clients to reduce their workload, clear up confusion and be confident that there is someplace to go when their health coverage questions need to be answered. Willamette Valley Benefits has been in business for more than 16 years and has grown through word of mouth, offering its services at no cost to those who need assistance. For more information visit WVBenefits.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/
November 03, 2022 01:00 PM Eastern Daylight Time
News ReleaseSoftware Effective Solutions Corp.
McapMediaWire -- Software Effective Solutions Corporation (OTC: SFWJ) (“The Company”, “SFWJ”) subsidiary Medcana has acquired a controlling stake in Eko2o Environmental Solutions S.A.S. of Medellin, Antioquia. a company focused on developing infrastructure for agriculture, primarily with greenhouse construction and irrigation systems in Colombia and South America. With this acquisition, the Company is expanding its infrastructure and overall capabilities toward additional market opportunities and strategic partnerships. Juan Ricardo Velez is CEO for Eko2o and is renown in the industry for his experience and track record for success. As well, execs are confident that the engineering talent and vendor support that comes with this acquisition will set Eko20 as a market leader in Colombia and South America very quickly. Gabriel Diáz, CEO of Medcana states “This acquisition further amplifies our investments in the industry and provides expansive opportunities for growth in the industry. We are honored to be working with a team equipped with a deep understanding of, and extensive experience in greenhouse and irrigation technologies. We are building something special here and Eko2o is a very important piece of our puzzle.” Juan Ricardo Velez CEO and founder of Eco2o is a Civil Engineer from University of Medellin, served and retired as army Major in Colombian Army. He has advanced studies in Israel and Spain focusing on irrigation systems and greenhouses. His experience and his team are unrivaled in Colombia and most of South America. About Software Effective Solutions/MedCana: Software Effective Solutions/MedCana is a global infrastructure and holding company in the cannabis industry. The recent acquisition of a software company expanded the offering to provide traceability from plant to product. MedCana's initial focus is on developing clients and companies in Latin America, with an initial focus on Colombia and partnerships with laboratories, research facilities, and hospitals throughout the world. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. Signed. /s/ Jose Gabriel Diaz, CEO www.medcana.net info@medcana.co FOR MORE INFORMATION PLEASE CONTACT: Chris Greta 512-587-5175 chris@chrisgreta.com www.medcana.net info@medcana.co Contact Details Chris Greta +1 512-587-5175 chris@chrisgreta.com Company Website https://www.medcana.net/
November 03, 2022 10:57 AM Eastern Daylight Time
News ReleaseShiftKey
ShiftKey, a leading technology platform bringing critical workforce solutions, was named the No. 1 fastest-growing privately held company in Dallas at the annual Dallas 100 Awards Gala, presented by Southern Methodist University’s Cox School of Business. The Dallas 100 recognizes the fastest-growing small, independent, privately held companies in North Texas based on three years of continuous revenue growth. To qualify for the Dallas 100, organizations must be headquartered in the Dallas-Fort Worth area and have revenue earnings of between $500,000 to $100 million dollars. “ShiftKey was born out of a vision to transform the workforce, creating opportunities for healthcare professionals to pursue independent, flexible opportunities while addressing serious workforce gaps to keep up with increased patient demand,” said Tom Ellis, CEO, ShiftKey. “We’re proud of our Dallas roots, so this honor means a lot to our team as we continue to position Dallas as a leading technology hub that brings real solutions to our workforce, healthcare systems and economy.” ShiftKey was founded in 2016 in Dallas by technology entrepreneur and innovator Tom Ellis. The company has experienced rapid growth, starting with 25 employees in 2016 and growing to 200 employees today. Since ShiftKey launched, more than 50 million hours in open shifts have been posted to its marketplace platform. The company has a network of 200,000 independent healthcare providers and partners with more than 3,000 healthcare facilities across 30+ states. Today, ShiftKey is the largest technology platform for connecting independent licensed healthcare professionals with open shifts at healthcare facilities across the United States. The company takes a marketplace approach, empowering the provider to determine when, where and how much they want to work, while giving healthcare facilities access to a vast network of professionals with diverse expertise and specializations to meet unique staffing needs in the moment. To learn more about ShiftKey’s exciting growth journey and opportunities for facilities and independent providers, follow ShiftKey on LinkedIn at https://www.linkedin.com/company/myshiftkey/. About ShiftKey Founded in 2016, Dallas-based ShiftKey is the largest technology platform for connecting independent licensed healthcare professionals with open shifts at healthcare facilities across the United States. Leveraging marketplace dynamics and deep industry knowledge, the company is playing a vital role in mitigating America’s healthcare staffing shortages, empowering providers to choose when, where and how much to work, while facilitating direct connections with healthcare facilities. Since its inception, healthcare facilities have posted more than 50 million hours of shifts on ShiftKey, gaining access to a vast talent network of licensed independent healthcare professionals with diverse expertise and specializations to meet their unique staffing needs in the moment. For more information, visit www.ShiftKey.com. Contact Details Curley Company for ShiftKey Lorianne Walker +1 410-688-1330 lorianne@curleycompany.com Company Website https://www.shiftkey.com/
November 03, 2022 10:32 AM Eastern Daylight Time
News ReleaseIAAC
- In Its 8th Year, the IAAC Literary Festival offers an intimate interaction with the leading minds and works of authors and poets writing about the Indian experience - The Indo-American Arts Council ( IAAC ), the organization dedicated to celebrating and showcasing the arts in North America, announced today the lineup for its eighth annual Literary Festival on November 7-13, 2022, in New York. Notable speakers, making in-person appearances at the Caelum Gallery (526 W 26th St.) in NY’s renowned Chelsea neighborhood, include Padma Shri, Barkha Dutt, Priya Kumari and Raza Mir. In continuation of its honored tradition, IAAC will also host a live Poetry Panel headlining Arundhathi Subramaniam and moderated by poetry curator, Dr. Ravi Shankar. Prior to the in-person weekend events, there will be a series of virtual events hosted on Facebook and YouTube each evening starting November 7-11 at 6:30 p.m. ET, which will feature ten writers including Nobel Peace Prize winner Kailash Satyarthi; London-based restaurateur and Netflix’s “Chef’s Table” star, Asma Khan with Michelin Chef Vikas Khanna - author of the world’s first “phygital” (physical and digital) cookbook; plus, actress, dancer and choreographer, Rukmini Vijayakumar. This series also includes a dedicated Children’s Literary Panel on Tuesday, November 8, 2022 which will showcase readings of “When Blackbirds Fly” by Hannah Lalhlanpuii and “Jamlo Walks” by Samina Mishra. "IAAC's Literary Festival showcases writers who bring stories of the Indian experience and ethos to the world. Even as they set new standards of literary excellence, they excite our imagination and shape humanity's future through their thought leadership. The festival attendees will become part of extraordinary conversations. Supporting the festival will be a stellar group of moderators who themselves are literary luminaries. As always there will be a focus on first time regional translations, children's literature and poetry," said Rakesh Kaul, Vice Chairman, IAAC. IAAC’s literary festival will be an intense two-day immersive experience featuring thought-provoking conversations, readings and discussions of stories told by courageous authors. Each authors' skill and expertise cover a wide range of civilizational and cultural topics including archeology, design, dance, history, compassion, wonder and the culinary arts. A panel of four poets will showcase powerful word-play that will make imaginations soar and speak directly to hearts, young and old. Refreshments, breakfast and lunch will be served, wine and cheese will accompany the poetry session. The festival wraps on a high note with the Annual Gala on November 13th. “At IAAC, we pride ourselves on our ability to seek out and find foundational storytellers who are not only noteworthy for their skill with language but whose seminal works also weave remarkable narratives that shape the world around them. This year is no exception; I have had the privilege to work with a dedicated team of literature lovers whose hard work and energy made this festival possible,” said Preethi Urs, Literary Festival Director, IAAC. A full list of writers and featured works below. For the full schedule with dates, times and moderators, please visit IAAC.us. Virtual Events (November 7-11): Kailash Satyarthi's greater body of work Ammu: Indian Home Cooking to Nourish your Soul (Interlink Books, May 2022) by Asma Khan Sacred Foods of India in NFT format (Akshaya, June 2022) by Vikas Khanna His Holiness the Dalai Lama in 100 Anecdotes (India Penguin, December 2022) by Arthy Muthanna Singh and Mamta Nainy The Dalai Lama: Leadership and the Power of Compassion (Interlink Books, November 2022) by Ginger Chih which includes a forward by His Holiness the Fourteenth Dalai Lama Finding Shiva: An Inner Journey of the Performative Experience (INDIC, 2021) by Rukmini Vijayakumar Virtual Children’s Panel: When Blackbirds Fly (Duckbill, February 2022) by Hannah Lalhlanpuii Jamlo Walks (India Puffin, September 2021) by Samina Mishra Somnath Hore: Wounds (Art1st, August 2021) conceptualized by Ritu Khoda, written by Likla Lall and featuring illustrator, Kripa (additionally, featuring in-person on November 13) In-Person Events (November 12-13): The Way of the Goddess: Daily Rituals to Awaken Your Inner Warrior and Discover Your True Self (TarcherPerigee, September 2022) by Ananta Ripa Ajmera Tata's Leadership Experiment: The Story of the Tata Administrative Service (HarperBusiness, August 2022) by Bharat Wakhlu, Mukund Rajan, Sonu Bhasin TO HELL AND BACK: Humans of COVID (Juggernaut, February 2022) by Barkha Dutt The Greatest Telugu Stories Ever Told (Rupa, March 2022) translated by Tamraparni Dasu and Dasu Krishnamoorty A Country Called Childhood: A Memoir (Aleph Book Company, July 2022) by Deepti Naval [Block] Chain Reaction - The Future of How We Live and Work (Soul Excellence Publishing, January 2022) by Elizebeth Varghese Tomb of Sand: A Novel by Geetanjali Shree (Tilted Axis Press, August 2021), translated by Daisy Rockwell Shehnai Virtuoso and Other Stories by Dhumketu (Deep Vellum Publishing, July 2022) translated by Jenny Bhatt Rajaraja Chola: King of Kings (Aleph Book Company, November 2022) by Kamini Dandapani Dava Shastri's Last Day (Grand Central Publishing, November 2021) by Kirthana Ramisetti A Matter of Trust (HarperCollins India, July 2021) by Meenakshi Ahamed The View from the Very Best House in Town (Walker Books US, February 2022) by Meera Trehan The Soul Catcher (Bodes Well Publishing, September 2021) by Monica Bhide Mirror Made of Rain (The Unnamed Press, May 2022) by Naheed Phiroze Patel The Candid Life of Meena Dave (Lake Union Publishing, June 2022) by Namrata Patel People of the Indus (India Penguin, November 2022) by Nikhil Gulati Leaf Talks Peace - Buddha's Message of Harmony (Eternal Tree Books, May 2022) by Priya Kumari Talent: The Market Cap Multiplier (Ideapress Publishing, January 2022) by Ram Charan and Anish Batlaw Murder at the Mushaira: A Novel (Rupa Publications India, January 2021) by Raza Mir Smashing the Patriarchy: A Guide for the 21st-Century Indian Woman (Rupa, November, 2021) by Sindhu Rajasekaran KALA - Essays on Contemporary Design Aesthetics (Times Group Books, 2020) edited by Padma Shri Sunita Kohli Somnath Hore: Wounds (Art1st, August 2021) conceptualized by Ritu Khoda, written by Likla Lall and featuring illustrator, Kripa Notable International Poets: Love Without a Story (Westland, April 2019) by Arundhathi Subramaniam My Body Lives Like a Threat (Flowersong Press, January 2022) by Megha Sood Time Regime (Gaudy Boy, March 2022) by Jhani Randhawa Singing in the Dark (Vintage Books, October 2020) edited by Nishi Chawla and K Satchidanandan Attendance Details: For a complete calendar of events between on November 7-13, 2022, visit https://iaac.us/iaac-literary-festival-2022/ RSVP for both in-person and online events at: https://www.eventbrite.com/e/iaac-literary-festival-2022-tickets-446199724387 Social Media for IAAC: Facebook: https://www.facebook.com/iaac.us YouTube: https://www.youtube.com/channel/UC7XldGWApKYy-IvQPapxFJg Twitter: https://twitter.com/IAArtsCouncil Instagram: https://www.instagram.com/iaacny Hashtag: #IAACLitFest For a full press kit including photos and posters: https://drive.google.com/drive/folders/1DtbCXBSbA25yTQmf7vfMEWcdWFOGszA-?usp=sharing For IAAC Suman Gollamudi, Executive Director, Indo-American Arts Council suman.gn@iaac.us About Indo-American Arts Council (IAAC): The IAAC supports all the artistic disciplines in classical, fusion, folk and innovative forms influenced by the arts of India. We work cooperatively with colleagues around the U.S. to broaden our collective audiences and to create a network for shared information, resources and funding. Our focus is to help artists and art organizations in North America as well as to facilitate artists from India to exhibit, perform and produce their work here. The IAAC is a 501(c)(3) tax-exempt organization. All donations are tax-deductible to the fullest extent allowable by law. For information, please visit www.iaac.us. For a full press kit including photos and posters: https://drive.google.com/drive/folders/1DtbCXBSbA25yTQmf7vfMEWcdWFOGszA-?usp=sharing Contact Details Indo-American Arts Council Suman Gollamudi, Executive Director suman.gn@iaac.us
November 02, 2022 04:57 PM Eastern Daylight Time
Image
News ReleaseIntus Care
Intus Care, developer of an innovative predictive analytics platform aimed at improving geriatric care outcomes, today announced the close of its Series A, securing over $14M led by Deerfield Management. Other undisclosed investors contributed to the raise through additional cash investments and conversion of existing debt. Founded in 2019 by Brown University undergraduate students, Intus Care’s mission is to empower geriatric care providers through data to deliver more effective patient management and treatment for dual-eligible seniors -- some of the most socially vulnerable and clinically complex people in the U.S. “We are extremely impressed both by the impact that Intus Care’s technology is poised to have on patient outcomes, and by the passion and dedication of its team,” said Dr. Julian Harris, operating partner at Deerfield Management. “We are proud to invest in a company we believe will be vital to revolutionizing geriatric care.” Intus Care’s technology platform enables care providers to mitigate preventable high-utilization events, track quality interventions, and equip healthcare management teams with vital actionable insights to make informed decisions for senior patients to improve their health outcomes. Its digital healthcare platform integrates with electronic health records, claims, and accounting software to highlight clinical risks in patients and display organizational data. This offers a holistic view of each patient in an organization, allowing healthcare teams to better plan, manage, and provide quality care to the most vulnerable senior populations in our communities. “To have an investor as esteemed in the healthcare industry as Deerfield Management recognize our value enough to lead our Series A is truly humbling,” said Robbie Felton, CEO and co-founder of Intus Care. “As a child, I watched my mother – then a geriatric social worker in Detroit – navigate the obstacles of caring for a disadvantaged population. Today, it makes me extremely proud to be providing caregivers with predictive analytics technology that will allow them to make more informed decisions for their patients that may lead to better outcomes.” Intus Care currently works with over 25 PACE Programs in 13 states who are utilizing its first-of-its-kind predictive analytics platform and entered a Letter of Understanding with the National PACE Association to pursue a strategic partnership. “Robbie and I are proud to be impacting the elder care space, and also hope to inspire other young entrepreneurs of color,” said Evan Jackson, COO and co-founder of Intus Care. “We are very appreciative to have earned the support of Deerfield Management and our other investors and are excited by the possibilities that their investment will enable us to actualize.” The latest investment round will position the company to maximize greater technological opportunities through data, honing product strategy that will support a major scale-up of their current service offerings. They also plan to grow their human capital by attracting, hiring, and retaining strong talent committed to their mission. About Intus Care Intus Care synthesizes data to improve care and reduce hospitalizations for some of the most socially vulnerable and clinically complex patients in today’s healthcare system – senior citizens. The company has created a unique data-driven predictive analytics platform designed for organizations such as PACE programs, nursing homes, long-term care facilities, and home care agencies. It easily integrates with existing electronic health records, claims, and financial software to automatically extract and analyze data. By highlighting participant risk and care-focused information, the Intus Care software empowers clinicians, nurses, and other care providers by informing decisions that improve outcomes and reduce unnecessary costs. Learn more at intuscare.com. Contact Details SVM Public Relations Jordan Bouclin +1 401-490-9700 intuscare@svmpr.com Company Website https://www.intuscare.com/
November 02, 2022 10:40 AM Eastern Daylight Time
Contact Us
Pricing
About us
Features
News Hub
Terms of Use
Privacy Policy